Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines

Rösner,Harald; Möller,Wolfgang; Groebner,Sabine; Torremante,Pompilio

doi:10.3892/ol.2016.4811

Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines

Authors:
- Harald Rösner
- Wolfgang Möller
- Sabine Groebner
- Pompilio Torremante
View Affiliations

Affiliations: Institute of Zoology, University of Hohenheim, D‑70593 Stuttgart, Germany, Synlab Medical Services, MCZ Synlab Leinfelden, D-70771 Leinfelden, Germany, Practice for Gynaecology and Obstetrics, D-88416 Ochsenhausen, Germany
Published online on: July 5, 2016 https://doi.org/10.3892/ol.2016.4811
Pages: 2159-2162

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical trials have revealed that molecular iodine (I2) has beneficial effects in fibrocystic breast disease and in cyclic mastalgia. Likewise, povidone-iodine (PVP-I), which is widely used in clinical practice as an antiseptic agent following tumour surgery, has been demonstrated to have cytotoxic effects on colon cancer and ascites tumour cells. Our previous study indicated that the growth of breast cancer and seven other human malignant cell lines was variably diminished by I2 and iodolactones. With the intention of developing an iodine‑based anticancer therapy, the present investigations extended these studies by comparing the cytotoxic capacities of I2, potassium iodide (KJ), PVP‑I and Lugol's solution on various human carcinoma cell lines. Upon staining the cell nuclei with Hoechst 33342, the cell densities were determined microscopically. While KJ alone did not affect cell proliferation, it enhanced the antiproliferative activity of I2. In addition, PVP‑I significantly inhibited the proliferation of human MCF‑7 breast carcinoma, IPC melanoma, and A549 and H1299 lung carcinoma cells in a concentration corresponding to 20 µM I2. Likewise, Lugol's solution in concentrations corresponding to 20‑80 µM I2 were observed to reduce the growth of MCF‑7 cells. Experiments with fresh human blood samples revealed that the antiproliferative activity of PVP‑I and I2 is preserved in blood plasma to a high degree. These findings suggest that PVP‑I, Lugol's solution, and a combination of iodide and I2 may be potent agents for use in the development of antitumour strategies.

View Figures

View References

1	Funahashi H, Imai F, Tanaka Y, Tobinaga J, Wada M, Morita T, Yamada F, Tsukamura K, Oiwa M, Kikumori T, et al: Suppressive effect of iodine on DMBA-induced breast tumour growth in the rat. J Surg Oncol. 61:209–213. 1996. View Article : Google Scholar : PubMed/NCBI
2	García-Solís P, Alfaro Y, Anguiano B, Delgado G, Guzman RC, Nandi S, Díaz-Muñoz M, Vázquez-Martínez O and Aceves C: Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment evidence that I2 prevents cancer promotion. Mol Cell Endocrinol. 236:49–57. 2005. View Article : Google Scholar : PubMed/NCBI
3	Eskin BA, Grotowski CE, Conolly CP and Ghent WR: Different tissue responses for iodine and iodide in rat thyroid and mammary glands. Biol Trace Elem Res. 49:9–19. 1995. View Article : Google Scholar : PubMed/NCBI
4	Ghent WR, Eskin BA, Low DA and Hill LP: Iodine replacement in fibrocystic disease of the breast. Can J Surg. 36:453–460. 2004.
5	Kessler JH: The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia. Breast J. 10:328–336. 2004. View Article : Google Scholar : PubMed/NCBI
6	Aceves C, Anguiana B and Delgado G: Is iodine a gatekeeper of the integrity of the mammary gland? J Mammary Gland Biol Neoplasia. 10:189–196. 2005. View Article : Google Scholar : PubMed/NCBI
7	Torremante P: Mastopathie, breast cancer and iodolactone. Dtsch Med Wochenschr. 129:641–645. 2004.(In German). View Article : Google Scholar : PubMed/NCBI
8	Sato S, Miyake M, Hazama A and Omori K: Povidone-iodine- induced cell deathin cultured human epithelial Hela cells and rat oral mucosa tissue. Drug Chem Toxicol. 37:269–275. 2014. View Article : Google Scholar
9	Arroyo-Helguera O, Anguiano B, Delgado G and Aceves C: Uptake and antiproliferative effect of molecular iodine in the MCF-7 breast cancer cell line. Endocr Relat Cancer. 13:1147–1158. 2006. View Article : Google Scholar : PubMed/NCBI
10	Shrivastava A, Tiwari M, Sinha RA, Kumar A, Balapure AK, Bajpai VK, Sharma R, Mitra K, Tandon A and Godbole MM: Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving mitochondria-mediated pathway. J Biol Chem. 28:19762–19771. 2006. View Article : Google Scholar
11	Rösner H, Torremante P, Möller W and Gärtner R: Antiproliferative/cytotoxic activity of molecular iodine and iodolactones in various human carcinoma cell lines. No interfering with EGF-signaling, but evidence for apoptosis. Exp Clin Endocrinol Diabetes. 118:410–419. 2010. View Article : Google Scholar : PubMed/NCBI
12	Nava-Villalba M, Nuñez-Anita RE, Bontempo A and Aceves C: Activation of peroxisome proliferator-activated receptor gamma is crucial for the antitumor effect of 6-iodolactone. Mol Cancer. 14:1682015. View Article : Google Scholar : PubMed/NCBI
13	Arroyo-Helguera O, Rojas E, et al: Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: Evidence that 6-iodolactone mediates apoptotic effects. Endocr Relat Cancer. 15:1003–1011. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sun P, Zhao J, Luo ZC, Zhang P, Chen P, Zhang XL, Luo S, Yang DB, Tan J, Zhou Y, et al: Diluted povidone-iodine inhibits tumour growth through apoptosis-induction and suppression of SOD activity. Oncol Rep. 27:383–388. 2012.PubMed/NCBI
15	Ghent WR, Eskin BA, Low DA and Hill LP: Iodine replacement in fibrocystic disease of the breast. Cancer J Surg. 36:453–460. 1993.
16	Aceves C, Anguiano B and Delgado G: The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. Thyroid. 23:938–946. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kessler JH: The effect of supraphysiological levels of iodine on patients with cyclic mastalgia. Breast J. 10:328–336. 2004. View Article : Google Scholar : PubMed/NCBI
18	Winkler R, Griebenow S and Wonisch W: Effect of iodide on total antioxidant status of human serum. Cell Biochem Funct. 18:143–146. 2000. View Article : Google Scholar : PubMed/NCBI
19	Delgado G, Muñoz-Torres C, Orozco-Esquivel T, Anguiano B and Aceves C: Total iodine quantification in fluids and tissues from iodine- or iodide-supplemented rats by ion chromatography following microwave-assisted digestion. Thyroid. 25:352–360. 2015. View Article : Google Scholar : PubMed/NCBI